Novus Therapeutics

Novus Therapeutics Reports Third Quarter 2020 Financial Results

Retrieved on: 
Monday, November 16, 2020
Health, Stem cells, Genetics, General Health, Clinical trials, Pharmaceutical, Biotechnology, Life sciences, Pharmaceutical industry, Biopharmaceutical, Biotechnology, Pharmacy, AT-1501, Novus Therapeutics

Novus Therapeutics, Inc. (Novus) (NASDAQ: NVUS), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines for patients undergoing organ or cellular transplantation, as well as those living with immunological diseases, today reported its financial results for the quarter ended September 30, 2020, and operational highlights.

Key Points: 
  • Novus Therapeutics, Inc. (Novus) (NASDAQ: NVUS), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines for patients undergoing organ or cellular transplantation, as well as those living with immunological diseases, today reported its financial results for the quarter ended September 30, 2020, and operational highlights.
  • Second, we financed Novus to have sufficient capital to execute up to four Phase 2 clinical trials with AT-1501 in different high-need indications.
  • R&D expenses were $615,000 for the three months ended September 30, 2020, compared to $1.5 million for the same period in 2019.
  • The company had $114.5 million in cash and cash equivalents as of September 30, 2020, compared to $8.8 million as of December 31, 2019.

Novus Therapeutics Announces First Patient Enrolled in Phase 2a Clinical Trial of Anti-CD40L Antibody AT-1501 in Amyotrophic Lateral Sclerosis

Retrieved on: 
Monday, November 2, 2020
Biotechnology, FDA, Health, Pharmaceutical, Clinical trials, Branches of biology, Medicine, Clinical medicine, Biomarkers, Biotechnology, Chemical pathology, AT-1501, Novus Therapeutics

We look forward to the safety and biomarker insights from this study and we anticipate top-line data from this important trial in 2022.

Key Points: 
  • We look forward to the safety and biomarker insights from this study and we anticipate top-line data from this important trial in 2022.
  • "There is strong evidence that the reduction of peripheral neuroinflammation has the capacity to influence disease progression in ALS, said Dr.
  • The AT-1501 Phase 2a trial in ALS is a 12-week, open label, dose escalating, safety and biomarker study.
  • Novus Therapeutics has completed a Phase 1a/1b single ascending dose trial in healthy volunteers and adults living with ALS.

Novus Therapeutics Announces Acquisition of Anelixis Therapeutics

Retrieved on: 
Monday, September 14, 2020
Biotechnology, FDA, Health, Finance, Pharmaceutical, Surgery, Professional services, Other Science, Research, Medical devices, Hospitals, Genetics, Science, Clinical trials, Clusters of differentiation, Broadband, Novus Entertainment, CD154, CD40, Telecommunications, Information and communications technology, the Transactions, AT-1501, Novus Therapeutics

Novus Therapeutics, Inc. (Novus) (NASDAQ: NVUS) today announced it has completed the acquisition of Anelixis Therapeutics, Inc. (Anelixis), a privately held clinical stage biotechnology company developing a next generation anti-CD40 Ligand (CD40L) antibody as a potential treatment for organ and cellular transplantation, autoimmune diseases, and neurodegenerative diseases.

Key Points: 
  • Novus Therapeutics, Inc. (Novus) (NASDAQ: NVUS) today announced it has completed the acquisition of Anelixis Therapeutics, Inc. (Anelixis), a privately held clinical stage biotechnology company developing a next generation anti-CD40 Ligand (CD40L) antibody as a potential treatment for organ and cellular transplantation, autoimmune diseases, and neurodegenerative diseases.
  • In addition to the strategic acquisition and private placement, Novus announced its Board of Directors has previously appointed David-Alexandre DA C. Gros, M.D.
  • Concurrent with the acquisition, former Anelixis Chairman of the Board Walter Ogier has been appointed to the Novus Board of Directors.
  • The acquisition was approved by the Board of Directors of Novus and the equity holders of Anelixis.

Novus Therapeutics Reports First Quarter 2020 Financial Results

Retrieved on: 
Friday, May 15, 2020
Pharmaceutical, Health, Clinical trials, Life sciences, Companies, Industries, Pernix Therapeutics Holdings, Study C-006, Novus Therapeutics

Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat, today announced financial results for the quarter ended March 31, 2020.

Key Points: 
  • Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat, today announced financial results for the quarter ended March 31, 2020.
  • The company had $11.8 million in cash and cash equivalents as of March 31, 2020.
  • Research and development (R&D) expenses were $1.6 million for the three months ended March 31, 2020, compared to $3.0 million for the same period in 2019.
  • Novus Therapeutics, Inc. (Novus) is a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat.

Novus Therapeutics Completes Enrollment of Phase 2a Trial of OP0201 in Pediatric Patients with Acute Otitis Media

Retrieved on: 
Monday, March 2, 2020
Pharmaceutical, Health, Clinical trials, Audiology, Otitis, Otitis media, Pediatrics, RTT, Medical specialties, Health, Life sciences, Study C-006, Novus Therapeutics

Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat, today announced that it has completed enrollment of the phase 2a trial of OP0201 in pediatric patients with acute otitis media (study C-006).

Key Points: 
  • Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat, today announced that it has completed enrollment of the phase 2a trial of OP0201 in pediatric patients with acute otitis media (study C-006).
  • The company enrolled a total of 103 patients into the clinical trial and expects to report data by early June 2020.
  • Completion of enrollment for this first OP0201 efficacy clinical trial marks a major milestone for our company, said Dr. Catherine Turkel, President of Novus Therapeutics.
  • Novus Therapeutics, Inc. (Novus) is a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat.

Novus Therapeutics Provides Update on OP0201

Retrieved on: 
Monday, January 13, 2020
Biotechnology, Pharmaceutical, Health, Clinical trials, Medical specialties, Medicine, Otitis, Pediatrics, RTT, Health, Audiology, Otitis media, Otorhinolaryngology, Study C-006, Novus Therapeutics

Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat, today provided an update on the ongoing phase 2a study C-006 in acute otitis media patients.

Key Points: 
  • Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat, today provided an update on the ongoing phase 2a study C-006 in acute otitis media patients.
  • The company plans to close enrollment in the first calendar quarter of 2020 once approximately 100 patients have been enrolled.
  • We look forward to completing the first OP0201 clinical trial in pediatric patients with acute otitis media, said Gregory J. Flesher, Chief Executive Officer.
  • Novus Therapeutics, Inc. (Novus) is a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat.